SCHEMBL19201599

SCHEMBL19201599

CCOC(=O)/C=C/S(=O)(=O)c1ccc(Br)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.67
LMNA P02545 7/20 0.67
ALDH1A1 P00352 7/20 0.67
NPSR1 Q6W5P4 4/20 0.67
MAPK1 P28482 3/20 0.67
HTT P42858 3/20 0.67
TP53 P04637 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
XBP1 P17861 1/20 0.67
AGTR1 P30556 1/20 0.67
KMT2A Q03164 3/20 0.47
TSHR P16473 1/20 0.47
RAB9A P51151 1/20 0.47
GFER P55789 1/20 0.47
NHERF1 O14745 1/20 0.46
MEN1 O00255 2/20 0.44
S1PR4 O95977 1/20 0.44
S1PR1 P21453 1/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19195341 0.88 ALDH1A1 (0.70) MAPTLMNAALDH1A1NPSR1MAPK1
SCHEMBL11841005 0.85 ALDH1A1 (0.67) MAPTLMNAALDH1A1NPSR1MAPK1
SCHEMBL19209521 0.84 MAPT (0.66) MAPTLMNAALDH1A1NPSR1MAPK1
SCHEMBL9542426 0.84 MAPT (0.66) MAPTLMNAALDH1A1NPSR1MAPK1
SCHEMBL19201601 0.83 LMNA (0.66) MAPTLMNAALDH1A1NPSR1MAPK1
SCHEMBL12477686 0.82 ALDH1A1 (0.64) MAPTLMNAALDH1A1NPSR1MAPK1
SCHEMBL12477690 0.82 ALDH1A1 (0.64) MAPTLMNAALDH1A1NPSR1MAPK1
SCHEMBL14134651 0.77 GAA (0.58) MAPTLMNAALDH1A1NPSR1MAPK1
SCHEMBL11832758 0.77 ALDH1A1 (0.67) MAPTLMNAALDH1A1NPSR1MAPK1
SCHEMBL11832751 0.77 ALDH1A1 (0.67) MAPTLMNAALDH1A1NPSR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114617868-A NRF2 activating compounds and uses thereof 参宿七制药股份有限公司 2022-06-14 CN claimed
CN-114617868-A NRF2 activating compounds and uses thereof 参宿七制药股份有限公司 2022-06-14 CN disclosed
CN-108699011-B NRF2 activating compounds and uses thereof 参宿七制药股份有限公司 2022-05-06 CN disclosed
EP-3411361-B1 NRF2 ACTIVATING COMPOUNDS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2020-11-25 EP disclosed
US-9845307-B2 Nrf2 activating compounds and uses thereof MIDCAP FINANCIAL TRUST 2017-12-19 US disclosed
WO-2017136589-A1 NRF2 ACTIVATING COMPOUNDS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2017-08-10 WO disclosed
US-20170217922-A1 Nrf2 Activating Compounds and Uses Thereof MIDCAP FINANCIAL TRUST 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217922-A1 Nrf2 Activating Compounds and Uses Thereof NFE2L2, KEAP1, NQO1 MAPT 2271/4885LMNA 2725/4885ALDH1A1 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.